Mpox Vaccine Candidate Has Shown Potential in Mice
A new mRNA-based vaccine protected immunocompromised mice from severe mpox, offering a potential path for future high-risk prevention.
Updated on Sept. 19, 2026 in Diseases — General
Live Poll
Does new vaccine research make you more confident in our ability to manage future viral outbreaks?
Researchers have developed a trivalent mRNA vaccine candidate, named AMA-IL-15, that protected immunocompromised mice against mpox. This experimental development aims to address the health risks mpox poses to vulnerable populations worldwide.
Why it matters
The global re-emergence of the mpox virus has created an urgent need for more effective prevention strategies. This candidate specifically targets high-risk groups who may be more susceptible to severe disease outcomes.
In a preclinical study, the AMA-IL-15 trivalent mRNA-LNP construct achieved complete survival in immunocompromised mice. The findings suggest the vaccine effectively stimulates both neutralizing antibody responses and T-cell activity.
The details
The AMA-IL-15 vaccine is a trivalent construct that co-expresses the A35R, M1R, and A29L antigens to prime the immune system. By incorporating IL-15, the vaccine boosts T follicular helper and germinal center B-cell activity to strengthen the long-term immune response. This dual approach improves the body's ability to clear the mpox virus from the lungs and mitigate early illness symptoms.
Timeline
September 19, 2026: The research findings were published.
Health Landscape
This development highlights the ongoing evolution of mRNA technology beyond its initial deployment in COVID-19. It aligns with broader efforts to engineer next-generation vaccines capable of providing durable protection for populations with weakened immune systems.
This research is in the experimental, preclinical stage and is not yet available for human use. Patients with immunocompromising conditions should continue to consult their physicians regarding existing, approved prevention strategies and mpox risk management.
The takeaway
The development of cytokine-armed mRNA vaccines represents a promising frontier in protecting immunocompromised individuals from viral threats. Stay informed on public health guidelines for mpox prevention and discuss any concerns regarding your personal immunity status with your primary care physician.
Further reading
For more on the current understanding of mpox and its treatment landscape, visit Diseases — General.
More information
Review the full details of this peer-reviewed research study for technical data.
Source note: This article includes information reported by Nature.
Live Poll
Does new vaccine research make you more confident in our ability to manage future viral outbreaks?
